Trial intelligence / Profile preview

Phase 3 open-label maintenance study of sodium zirconium cyclosilicate in hyperkalemia

2014-004555-31Phase 3Completed

Sponsor
ZS Pharma
Start
Mar 2015
Modality
DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 3, open-label, single-arm trial of sodium zirconium cyclosilicate in hyperkalemia, sponsored by ZS Pharma. Primary endpoint: Safety and tolerability during open-label maintenance. Started Mar 2015; status: completed.

02

Drugs

sodium zirconium cyclosilicate
03

Conditions

hyperkalemia

Beyond the preview

Go deeper on 2014-004555-31.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2014-004555-31.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call